((自动化翻译由路透提供，请见免责声明 ))
10月7日 - ** 券商Evercore ISI将合同研究公司Charles River Laboratories International 的评级从 "跑赢大盘 "下调至 "与大盘持平"，并将PT从225美元下调至190美元。
** 在跟踪CRL的20位分析师中，Evercore的PT是第二低的。
** 券商称，制药研发支出前景恶化可能会在未来6-12个月内拖累对该公司服务的临床前需求
** Evercore表示，需求下滑将拖累收入增长和盈利能力，并将2025年的每股收益预期从11.01美元下调至10.09美元。
** 20位跟踪CRL的分析师的平均评级为 "持有"；他们的中位预测值为212.50美元 - LSEG
** 截至上一交易日收盘，股价累计下跌19.3%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.